Test verification and validation for molecular diagnostic assays
- PMID: 22208481
- DOI: 10.5858/arpa.2011-0212-ED
Test verification and validation for molecular diagnostic assays
Abstract
With our ever-increasing understanding of the molecular basis of disease, clinical laboratories are implementing a variety of molecular diagnostic tests to aid in the diagnosis of hereditary disorders, detection and monitoring of cancer, determination of prognosis and guidance for cancer therapy, and detection and monitoring of infectious diseases. Before introducing any new test into the clinical laboratory, the performance characteristics of the assay must be "verified," if it is a US Food and Drug Administration (FDA)-approved or FDA-cleared test, or "validated," if it is a laboratory-developed test. Although guidelines exist for how validation and verification studies may be addressed for molecular assays, the specific details of the approach used by individual laboratories is rarely published. Many laboratories, especially those introducing new types of molecular assays, would welcome additional guidance, especially in the form of specific examples, on the process of preparing a new molecular assay for clinical use.
Similar articles
-
Verification of performance specifications for a US Food and Drug Administration-approved molecular microbiology test: Clostridium difficile cytotoxin B using the Becton, Dickinson and Company GeneOhm Cdiff assay.Arch Pathol Lab Med. 2012 Jan;136(1):20-5. doi: 10.5858/arpa.2011-0138-OA. Arch Pathol Lab Med. 2012. PMID: 22208483
-
Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array.Arch Pathol Lab Med. 2012 Jan;136(1):14-9. doi: 10.5858/arpa.2010-0536-OA. Arch Pathol Lab Med. 2012. PMID: 22208482
-
Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene.Arch Pathol Lab Med. 2012 Jan;136(1):47-52. doi: 10.5858/arpa.2010-0645-SA. Arch Pathol Lab Med. 2012. PMID: 22208487
-
Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory.Hum Mutat. 2002 Apr;19(4):324-33. doi: 10.1002/humu.10061. Hum Mutat. 2002. PMID: 11933187 Review.
-
[Diagnostic kits in parasitology: which controls?].Parassitologia. 2004 Jun;46(1-2):145-9. Parassitologia. 2004. PMID: 15305705 Review. Italian.
Cited by
-
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Arch Pathol Lab Med. 2013 Jun;137(6):828-60. doi: 10.5858/arpa.2012-0720-OA. Epub 2013 Apr 3. Arch Pathol Lab Med. 2013. PMID: 23551194 Free PMC article.
-
Molecular Biomarkers for the Evaluation of Colorectal Cancer.Am J Clin Pathol. 2017 Mar;147(3):221-260. doi: 10.1093/ajcp/aqw209. Epub 2017 Feb 3. Am J Clin Pathol. 2017. PMID: 28165529 Free PMC article.
-
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.J Thorac Oncol. 2013 Jul;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f. J Thorac Oncol. 2013. PMID: 23552377 Free PMC article.
-
Critical evaluation of FDA-approved respiratory multiplex assays for public health surveillance.Expert Rev Mol Diagn. 2018 Jul;18(7):631-643. doi: 10.1080/14737159.2018.1487294. Epub 2018 Jun 19. Expert Rev Mol Diagn. 2018. PMID: 29886764 Free PMC article. Review.
-
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper.Virchows Arch. 2025 Jul 17. doi: 10.1007/s00428-025-04169-4. Online ahead of print. Virchows Arch. 2025. PMID: 40670724
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources